Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;37(7):1345-1351.
doi: 10.1097/IAE.0000000000001364.

OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT

Eric K Chin  1 , David R P Almeida, Gabriel Velez, Kunyong Xu, Maria Peraire, Maria Corbella, Yasser M Elshatory, Young H Kwon, Karen M Gehrs, H Culver Boldt, Elliott H Sohn, Stephen R Russell, James C Folk, Vinit B Mahajan
Affiliations

OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT

Eric K Chin et al. Retina. 2017 Jul.

Abstract

Purpose: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).

Methods: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline.

Results: Ninety-four injections in 52 patients (59 eyes) were reviewed. Forty eyes received a single injection, and 19 eyes received multiple injections. Ocular hypertension developed in 14 patients (26.9%). Thirteen patients (25%) had preexisting glaucoma or suspicion of glaucoma, and 6 of these developed OHT. Glaucoma eye drops were initiated after 13 injections (13.8%). Invasive surgery for glaucoma was required in 3 patients (3.2%): all had glaucoma or suspicion of glaucoma (one case was related to neovascular glaucoma and unlikely related to steroid response after Ozurdex). There was no difference in relative intraocular pressure increase (i.e., difference between final follow-up or subsequent intravitreal injection vs. baseline) between single versus multiple Ozurdex injections (P = 0.883).

Conclusion: Patients (26.9%) who received Ozurdex developed OHT. Glaucoma or glaucoma-suspicion factors were present in all patients who required invasive surgery for glaucoma. A greater proportion of patients who received multiple injections had an intraocular pressure elevation, but the relative intraocular pressure increase was not significant.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Average intraocular pressure (IOP) at baseline and subsequent follow-up relative to the time of initial injection among all patients (1A), and separated by clinical indication (1B).
FIGURE 2
FIGURE 2
Proportion of patients with and without glaucoma or glaucoma suspicion who experienced a relative increase in intraocular pressure of ≥10 mmHg (1A), and the proportion of patients with and without glaucoma or glaucoma suspicion who experienced a single IOP measurement of ≥30 mmHg after Ozurdex injection (1B).
FIGURE 3
FIGURE 3
Comparison between patients who had single versus multiple Ozurdex injections and the number of eyes that experienced an intraocular pressure increase of ≥10 mmHg (3A). Kaplan-Meier survival curve comparing single versus multiple Ozurdex injections (3B). The mean IOP elevation (difference between maximum follow-up and baseline) was compared between single versus multiple Ozurdex injections (3C).
See this image and copyright information in PMC

References

    1. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29:46–51. - PubMed
    1. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–296. - PubMed
    1. Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–2460. - PubMed
    1. Zarranz-Ventura J, Carreno E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158:1136–1145. - PubMed
    1. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema. Ophthalmology. 2014;121:2473–2481. - PubMed